COMPOSITION COMPRISING CHEMOKINE INHIBITOR, COLONY STIMULATING FACTOR INHIBITOR, AND CANCER IMMUNOTHERAPY AGENT FOR PREVENTION OR TREATMENT OF CANCER AND COMBINATION THERAPY

摘要

The present invention relates to a composition comprising a chemokine inhibitor, a colony stimulating factor inhibitor, and an cancer immunotherapy agent for treatment of cancer, and combination therapy, and more specifically, to a pharmaceutical composition comprising a CXCL12 inhibitor, a colony stimulating factor 1 (CSF1) inhibitor, and a cancer immunotherapy agent for prevention and/or treatment of cancer, wherein the pharmaceutical composition increases the infiltration and activity of CD8 cytotoxic T cells in cancers resistant to cancer immunotherapy agents, especially PD-1/PD-L1 immune checkpoint inhibitors, to effectively reduce tumor sizes and thus is useful for prevention and treatment of cancers resistant to immunotherapy agents, especially cancers overexpressing p16^INK4A.